Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells

In this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic model...

Descripción completa

Detalles Bibliográficos
Autores: Vives, Marta, Ginestà, Mireia M., Gracova, Kristina, Graupera i Garcia-Milà, Mariona, Casanovas i Casanovas, Oriol, Capellá, G. (Gabriel), Serrano Piñol, M. Teresa, Laquente, Berta, Viñals Canals, Francesc
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2013
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/120265
Acceso en línea:https://hdl.handle.net/2445/120265
Access Level:acceso abierto
Palabra clave:Quimioteràpia del càncer
Medicaments antineoplàstics
Angiogènesi
Cèl·lules mare
Cèl·lules canceroses
Cancer chemotherapy
Antineoplastic agents
Neovascularization
Stem cells
Cancer cells
id ES_df8feb9f7b8e47b8d3d2c58bc9c1cd53
oai_identifier_str oai:recercat.cat:2445/120265
network_acronym_str ES
network_name_str España
repository_id_str
spelling Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cellsVives, MartaGinestà, Mireia M.Gracova, KristinaGraupera i Garcia-Milà, MarionaCasanovas i Casanovas, OriolCapellá, G. (Gabriel)Serrano Piñol, M. TeresaLaquente, BertaViñals Canals, FrancescQuimioteràpia del càncerMedicaments antineoplàsticsAngiogènesiCèl·lules mareCèl·lules cancerosesCancer chemotherapyAntineoplastic agentsNeovascularizationStem cellsCancer cellsIn this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic models and with cyclophosphamide in an orthotopic ovarian cancer model. In both models, the C-S schedule had the most favourable effect, achieving at least 80% tumour growth inhibition without increased toxicity. Moreover, in the pancreatic cancer model, although peritoneal metastases were observed in control and MTD groups, no dissemination was observed in the MET and C-S groups. C-S treatment caused a decrease in angiogenesis, and its effect on tumour growth was similar to that produced by the MTD followed by anti-angiogenic DC101 treatment. C-S treatment combined an increase in thrombospondin-1 expression with a decrease in the number of CD133+ cancer cells and triple-positive CD133+/CD44+/CD24+ cancer stem cells (CSCs). These findings confirm that the C-S schedule is a challenging clinical strategy with demonstrable inhibitory effects on tumour dissemination, angiogenesis and CSCs.Wiley2018201820132018info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersion9 p.application/pdfhttps://hdl.handle.net/2445/120265Articles publicats en revistes (Ciències Fisiològiques)reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésVersió postprint del document publicat a: https://doi.org/10.1002/ijc.28259International Journal of Cancer, 2013, vol. 133, num. 10, p. 2464-2472https://doi.org/10.1002/ijc.28259(c) Union for International Cancer Control (UICC), 2013info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1202652026-05-29T05:05:01Z
dc.title.none.fl_str_mv Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
title Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
spellingShingle Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
Vives, Marta
Quimioteràpia del càncer
Medicaments antineoplàstics
Angiogènesi
Cèl·lules mare
Cèl·lules canceroses
Cancer chemotherapy
Antineoplastic agents
Neovascularization
Stem cells
Cancer cells
title_short Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
title_full Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
title_fullStr Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
title_full_unstemmed Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
title_sort Meetronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells
dc.creator.none.fl_str_mv Vives, Marta
Ginestà, Mireia M.
Gracova, Kristina
Graupera i Garcia-Milà, Mariona
Casanovas i Casanovas, Oriol
Capellá, G. (Gabriel)
Serrano Piñol, M. Teresa
Laquente, Berta
Viñals Canals, Francesc
author Vives, Marta
author_facet Vives, Marta
Ginestà, Mireia M.
Gracova, Kristina
Graupera i Garcia-Milà, Mariona
Casanovas i Casanovas, Oriol
Capellá, G. (Gabriel)
Serrano Piñol, M. Teresa
Laquente, Berta
Viñals Canals, Francesc
author_role author
author2 Ginestà, Mireia M.
Gracova, Kristina
Graupera i Garcia-Milà, Mariona
Casanovas i Casanovas, Oriol
Capellá, G. (Gabriel)
Serrano Piñol, M. Teresa
Laquente, Berta
Viñals Canals, Francesc
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Quimioteràpia del càncer
Medicaments antineoplàstics
Angiogènesi
Cèl·lules mare
Cèl·lules canceroses
Cancer chemotherapy
Antineoplastic agents
Neovascularization
Stem cells
Cancer cells
topic Quimioteràpia del càncer
Medicaments antineoplàstics
Angiogènesi
Cèl·lules mare
Cèl·lules canceroses
Cancer chemotherapy
Antineoplastic agents
Neovascularization
Stem cells
Cancer cells
description In this article, the effectiveness of a multi-targeted chemo-switch (C-S) schedule that combines metronomic chemotherapy (MET) after treatment with the maximum tolerated dose (MTD) is reported. This schedule was tested with gemcitabine in two distinct human pancreatic adenocarcinoma orthotopic models and with cyclophosphamide in an orthotopic ovarian cancer model. In both models, the C-S schedule had the most favourable effect, achieving at least 80% tumour growth inhibition without increased toxicity. Moreover, in the pancreatic cancer model, although peritoneal metastases were observed in control and MTD groups, no dissemination was observed in the MET and C-S groups. C-S treatment caused a decrease in angiogenesis, and its effect on tumour growth was similar to that produced by the MTD followed by anti-angiogenic DC101 treatment. C-S treatment combined an increase in thrombospondin-1 expression with a decrease in the number of CD133+ cancer cells and triple-positive CD133+/CD44+/CD24+ cancer stem cells (CSCs). These findings confirm that the C-S schedule is a challenging clinical strategy with demonstrable inhibitory effects on tumour dissemination, angiogenesis and CSCs.
publishDate 2013
dc.date.none.fl_str_mv 2013
2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/120265
url https://hdl.handle.net/2445/120265
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1002/ijc.28259
International Journal of Cancer, 2013, vol. 133, num. 10, p. 2464-2472
https://doi.org/10.1002/ijc.28259
dc.rights.none.fl_str_mv (c) Union for International Cancer Control (UICC), 2013
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Union for International Cancer Control (UICC), 2013
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 9 p.
application/pdf
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv Articles publicats en revistes (Ciències Fisiològiques)
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422074973388800
score 15,81155

Similares en LA Referencia